Neuren Pharmaceuticals (NEU) Stock Overview
A biopharmaceutical company, develops drugs for the treatment of neurological disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
NEU passed our risk checks.
NEU Community Fair Values
Create NarrativeSee what 88 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Neuren Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$14.54 |
| 52 Week High | AU$22.99 |
| 52 Week Low | AU$11.00 |
| Beta | 1.56 |
| 1 Month Change | 16.69% |
| 3 Month Change | 11.42% |
| 1 Year Change | 4.76% |
| 3 Year Change | 7.46% |
| 5 Year Change | 1,053.97% |
| Change since IPO | 96.49% |
Recent News & Updates
Recent updates
NEU: Share Buyback Plan Will Support Bullish Long Term Outlook
Analysts have trimmed their 12 month price target for Neuren Pharmaceuticals from A$24.51 to A$23.45 as they factor in updated assumptions for discount rates, revenue growth, profit margins and future P/E multiples. What's in the News Neuren Pharmaceuticals Limited (ASX:NEU) has announced a share repurchase program covering up to 6,350,631 shares, equal to 5% of its issued share capital, with all repurchased shares to be cancelled (company announcement).Slammed 30% Neuren Pharmaceuticals Limited (ASX:NEU) Screens Well Here But There Might Be A Catch
The Neuren Pharmaceuticals Limited ( ASX:NEU ) share price has fared very poorly over the last month, falling by a...Investors Shouldn't Be Too Comfortable With Neuren Pharmaceuticals' (ASX:NEU) Earnings
Unsurprisingly, Neuren Pharmaceuticals Limited's ( ASX:NEU ) stock price was strong on the back of its healthy earnings...Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Is Well Worth Watching
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Neuren Pharmaceuticals Limited (ASX:NEU) Shares Fly 26% But Investors Aren't Buying For Growth
Despite an already strong run, Neuren Pharmaceuticals Limited ( ASX:NEU ) shares have been powering on, with a gain of...Neuren Pharmaceuticals Limited (ASX:NEU) Shares Fly 30% But Investors Aren't Buying For Growth
Neuren Pharmaceuticals Limited ( ASX:NEU ) shareholders would be excited to see that the share price has had a great...
DAYBUE And NNZ-2591 Will Expand Markets While Facing Regulatory Risks
Strong financial position and partnerships reduce the need for capital raising, protecting margins and earnings.Investors Don't See Light At End Of Neuren Pharmaceuticals Limited's (ASX:NEU) Tunnel
With a price-to-earnings (or "P/E") ratio of 10.1x Neuren Pharmaceuticals Limited ( ASX:NEU ) may be sending bullish...A Look At The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)
Key Insights The projected fair value for Neuren Pharmaceuticals is AU$13.55 based on 2 Stage Free Cash Flow to Equity...Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Is Well Worth Watching
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...New Forecasts: Here's What Analysts Think The Future Holds For Neuren Pharmaceuticals Limited (ASX:NEU)
Neuren Pharmaceuticals Limited ( ASX:NEU ) shareholders will have a reason to smile today, with the analysts making...Neuren Pharmaceuticals Limited's (ASX:NEU) Shares Climb 26% But Its Business Is Yet to Catch Up
Neuren Pharmaceuticals Limited ( ASX:NEU ) shares have had a really impressive month, gaining 26% after a shaky period...Calculating The Intrinsic Value Of Neuren Pharmaceuticals Limited (ASX:NEU)
Key Insights Neuren Pharmaceuticals' estimated fair value is AU$15.24 based on 2 Stage Free Cash Flow to Equity Neuren...Neuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models
The half-year results for Neuren Pharmaceuticals Limited ( ASX:NEU ) were released last week, making it a good time to...Pinning Down Neuren Pharmaceuticals Limited's (ASX:NEU) P/S Is Difficult Right Now
Neuren Pharmaceuticals Limited's ( ASX:NEU ) price-to-sales (or "P/S") ratio of 8.6x might make it look like a strong...Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Might Deserve Your Attention Today
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Getting In Cheap On Neuren Pharmaceuticals Limited (ASX:NEU) Is Unlikely
You may think that with a price-to-sales (or "P/S") ratio of 10.8x Neuren Pharmaceuticals Limited ( ASX:NEU ) is a...An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 41% Undervalued
Key Insights Neuren Pharmaceuticals' estimated fair value is AU$35.92 based on 2 Stage Free Cash Flow to Equity Current...Forecast: Analysts Think Neuren Pharmaceuticals Limited's (ASX:NEU) Business Prospects Have Improved Drastically
Neuren Pharmaceuticals Limited ( ASX:NEU ) shareholders will have a reason to smile today, with the analysts making...Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Neuren Pharmaceuticals Limited's (ASX:NEU) 51% Jump Shows Its Popularity With Investors
Despite an already strong run, Neuren Pharmaceuticals Limited ( ASX:NEU ) shares have been powering on, with a gain of...Need To Know: Analysts Are Much More Bullish On Neuren Pharmaceuticals Limited (ASX:NEU) Revenues
Neuren Pharmaceuticals Limited ( ASX:NEU ) shareholders will have a reason to smile today, with the analysts making...Calculating The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)
Key Insights Neuren Pharmaceuticals' estimated fair value is AU$15.62 based on 2 Stage Free Cash Flow to Equity With...This Just In: Analysts Are Boosting Their Neuren Pharmaceuticals Limited (ASX:NEU) Outlook for This Year
Neuren Pharmaceuticals Limited ( ASX:NEU ) shareholders will have a reason to smile today, with the analysts making...Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business
Just because a business does not make any money, does not mean that the stock will go down. By way of example, Neuren...Shareholder Returns
| NEU | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | 6.4% | 0.4% | 1.0% |
| 1Y | 4.8% | -15.0% | 3.1% |
Return vs Industry: NEU exceeded the Australian Pharmaceuticals industry which returned -15% over the past year.
Return vs Market: NEU exceeded the Australian Market which returned 3.1% over the past year.
Price Volatility
| NEU volatility | |
|---|---|
| NEU Average Weekly Movement | 7.3% |
| Pharmaceuticals Industry Average Movement | 10.4% |
| Market Average Movement | 10.3% |
| 10% most volatile stocks in AU Market | 17.4% |
| 10% least volatile stocks in AU Market | 4.2% |
Stable Share Price: NEU has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: NEU's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | Jon Pilcher | www.neurenpharma.com |
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins.
Neuren Pharmaceuticals Limited Fundamentals Summary
| NEU fundamental statistics | |
|---|---|
| Market cap | AU$1.84b |
| Earnings (TTM) | AU$30.44m |
| Revenue (TTM) | AU$64.65m |
Is NEU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NEU income statement (TTM) | |
|---|---|
| Revenue | AU$64.65m |
| Cost of Revenue | AU$36.39m |
| Gross Profit | AU$28.26m |
| Other Expenses | -AU$2.18m |
| Earnings | AU$30.44m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.24 |
| Gross Margin | 43.71% |
| Net Profit Margin | 47.08% |
| Debt/Equity Ratio | 0% |
How did NEU perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/30 05:58 |
| End of Day Share Price | 2026/05/29 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Neuren Pharmaceuticals Limited is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Melissa Benson | Barrenjoey Markets Pty Limited |
| Thomas Wakim | Bell Potter |
| Elyse Shapiro | Canaccord Genuity |